Literature DB >> 22929858

Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.

Ryan Baker1, Gang Han, Siriporn Sarangkasiri, MaryLou DeMarco, Carolyn Turke, Craig W Stevens, Thomas J Dilling.   

Abstract

PURPOSE: To report clinical and dosimetric factors predictive of radiation pneumonitis (RP) in patients receiving lung stereotactic body radiation therapy (SBRT) from a series of 240 patients. METHODS AND MATERIALS: Of the 297 isocenters treating 263 patients, 240 patients (n=263 isocenters) had evaluable information regarding RP. Age, gender, current smoking status and pack-years, O2 use, Charlson Comorbidity Index, prior lung radiation therapy (yes/no), dose/fractionation, V5, V13, V20, Vprescription, mean lung dose, planning target volume (PTV), total lung volume, and PTV/lung volume ratio were recorded.
RESULTS: Twenty-nine patients (11.0%) developed symptomatic pneumonitis (26 grade 2, 3 grade 3). The mean V20 was 6.5% (range, 0.4%-20.2%), and the average mean lung dose was 5.03 Gy (0.547-12.2 Gy). In univariable analysis female gender (P=.0257) and Charlson Comorbidity index (P=.0366) were significantly predictive of RP. Among dosimetric parameters, V5 (P=.0186), V13 (P=.0438), and Vprescription (where dose=60 Gy) (P=.0128) were significant. There was only a trend toward significance for V20 (P=.0610). Planning target volume/normal lung volume ratio was highly significant (P=.0024). In multivariable analysis the clinical factors of female gender, pack-years smoking, and larger gross internal tumor volume and PTV were predictive (P=.0094, .0312, .0364, and .052, respectively), but no dosimetric factors were significant.
CONCLUSIONS: Rate of symptomatic RP was 11%. Our mean lung dose was <600 cGy in most cases and V20<10%. In univariable analysis, dosimetric factors were predictive, while tumor size (or tumor/lung volume ratio) played a role in multivariable and univariable and analysis, respectively.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22929858     DOI: 10.1016/j.ijrobp.2012.03.041

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  60 in total

Review 1.  Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer.

Authors:  Joshua D Palmer; Nicholas G Zaorsky; Matthew Witek; Bo Lu
Journal:  J Thorac Dis       Date:  2014-04       Impact factor: 2.895

2.  Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.

Authors:  Mitsuru Okubo; Tomohiro Itonaga; Tatsuhiko Saito; Sachika Shiraishi; Ryuji Mikami; Hidetugu Nakayama; Akira Sakurada; Shinji Sugahara; Kiyoshi Koizumi; Koichi Tokuuye
Journal:  Br J Radiol       Date:  2017-04-06       Impact factor: 3.039

3.  Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.

Authors:  S Arcangeli; L Agolli; L Portalone; M R Migliorino; M G Lopergolo; A Monaco; J Dognini; M C Pressello; S Bracci; V Donato
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

4.  Effectiveness of robust optimization in volumetric modulated arc therapy using 6 and 10 MV flattening filter-free beam therapy planning for lung stereotactic body radiation therapy with a breath-hold technique.

Authors:  Hideharu Miura; Shuichi Ozawa; Yoshiko Doi; Minoru Nakao; Katsumaro Kubo; Masahiko Kenjo; Yasushi Nagata
Journal:  J Radiat Res       Date:  2020-07-06       Impact factor: 2.724

5.  Molecular and cellular profiling of acute responses to total body radiation exposure in ovariectomized female cynomolgus macaques.

Authors:  Ryne J DeBo; Thomas C Register; David L Caudell; Gregory D Sempowski; Gregory Dugan; Shauna Gray; Kouros Owzar; Chen Jiang; J Daniel Bourland; Nelson J Chao; J Mark Cline
Journal:  Int J Radiat Biol       Date:  2015-04-22       Impact factor: 2.694

Review 6.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Authors:  Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-25       Impact factor: 7.038

Review 7.  A survey of changing trends in modelling radiation lung injury in mice: bringing out the good, the bad, and the uncertain.

Authors:  Mohamad B Dabjan; Carolyn Ms Buck; Isabel L Jackson; Zeljko Vujaskovic; Brian Marples; Julian D Down
Journal:  Lab Invest       Date:  2016-08-01       Impact factor: 5.662

8.  Cleaning the dose falloff in lung SBRT plan.

Authors:  Dharmin Desai; Ganesh Narayanasamy; Milan Bimali; Ivan Cordrey; Hisham Elasmar; Senthamizhchelvan Srinivasan; Ellis Lee Johnson
Journal:  J Appl Clin Med Phys       Date:  2020-12-07       Impact factor: 2.102

Review 9.  Radiation pneumonitis after stereotactic radiation therapy for lung cancer.

Authors:  Hideomi Yamashita; Wataru Takahashi; Akihiro Haga; Keiichi Nakagawa
Journal:  World J Radiol       Date:  2014-09-28

10.  Optimizing the flattening filter free beam selection in RapidArc®-based stereotactic body radiotherapy for Stage I lung cancer.

Authors:  J-Y Lu; Z Lin; P-X Lin; B-T Huang
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.